Kennady Knox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kennady Knox has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Cong Xing
Department of Immunology, University of Texas Southwestern Medical Center
13 shared publications - Devon Jeltema
Department of Immunology, University of Texas Southwestern Medical Center
13 shared publications - Kun Yang
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA
13 shared publications - Nan Yan
Department of Immunology, University of Texas Southwestern Medical Center
13 shared publications - Nicole Dobbs
University of Texas Southwestern Medical Center 1 Department of Immunology Dallas, TX
13 shared publications - Zhen Tang
Department of Immunology, UT Southwestern Medical Center, Dallas, Texas
12 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Three-prime repair exonuclease 1 (TREX1) is the major DNase in mammalian cells that degrades cytosolic DNA to prevent activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway. Genotoxic stress, DNA damage, and radiotherapy induce TREX1 expression in cancer cells, allowing them to evade innate immune activation of type I IFN–mediated antitumor response. Therefore, targeting TREX1 could represent a potential approach to stimulate antitumor immunity. In this study, we conducted a high-throughput small-molecule inhibitor screen of TREX1 using a cell-free DNase assay. Compound 296 specifically inhibited TREX1 DNase activity at low micromolar concentrations, induced type I IFN signaling in cancer cells, and inhibited tumor growth in mice in an inteferon alpha/beta receptor (IFNAR)–dependent manner. Treatment with compound 296 also stimulated T-cell infiltration into tumors and synergized with immune checkpoint blockade. Trex1 knockout cancer cells elicited robust systemic antitumor immunity through tumor-intrinsic cGAS–STING activation and functioned as autologous cancer vaccines that protected against tumor challenge and metastasis. An inducible whole-body Trex1 knockout mouse model was established to simulate “on-demand” systemic TREX1 inactivation in adult mice. Sustained TREX1 loss suppressed a broad range of solid and metastatic tumors in adult mice without incurring severe immune toxicity, even when combined with immune checkpoint blockade, demonstrating the feasibility of an immune-safe therapeutic window. Together, these data demonstrate the antitumor efficacy and immune safety of multiple therapeutic modalities targeting TREX1, including targeting small-molecule inhibitors of TREX1 and employing TREX1 knockout tumor cells as an autologous cancer vaccine. These approaches should pave the way for developing TREX1-targeted cancer immunotherapies.Significance:Therapeutic modalities targeting TREX1 can activate cGAS-STING signaling and can be incorporated into autologous cancer vaccine designs to improve cancer treatment, supporting the potential of inactivating TREX1 to harness innate immunity.See related commentary by Hanks, p. 2778
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Three-prime repair exonuclease 1 (TREX1) is the major DNase in mammalian cells that degrades cytosolic DNA to prevent activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway. Genotoxic stress, DNA damage, and radiotherapy induce TREX1 expression in cancer cells, allowing them to evade innate immune activation of type I IFN–mediated antitumor response. Therefore, targeting TREX1 could represent a potential approach to stimulate antitumor immunity. In this study, we conducted a high-throughput small-molecule inhibitor screen of TREX1 using a cell-free DNase assay. Compound 296 specifically inhibited TREX1 DNase activity at low micromolar concentrations, induced type I IFN signaling in cancer cells, and inhibited tumor growth in mice in an inteferon alpha/beta receptor (IFNAR)–dependent manner. Treatment with compound 296 also stimulated T-cell infiltration into tumors and synergized with immune checkpoint blockade. Trex1 knockout cancer cells elicited robust systemic antitumor immunity through tumor-intrinsic cGAS–STING activation and functioned as autologous cancer vaccines that protected against tumor challenge and metastasis. An inducible whole-body Trex1 knockout mouse model was established to simulate “on-demand” systemic TREX1 inactivation in adult mice. Sustained TREX1 loss suppressed a broad range of solid and metastatic tumors in adult mice without incurring severe immune toxicity, even when combined with immune checkpoint blockade, demonstrating the feasibility of an immune-safe therapeutic window. Together, these data demonstrate the antitumor efficacy and immune safety of multiple therapeutic modalities targeting TREX1, including targeting small-molecule inhibitors of TREX1 and employing TREX1 knockout tumor cells as an autologous cancer vaccine. These approaches should pave the way for developing TREX1-targeted cancer immunotherapies.Significance:Therapeutic modalities targeting TREX1 can activate cGAS-STING signaling and can be incorporated into autologous cancer vaccine designs to improve cancer treatment, supporting the potential of inactivating TREX1 to harness innate immunity.See related commentary by Hanks, p. 2778
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
RZ score, qAC50 and toxicity of 41 potent TREX1 inhibitors from the small-molecule inhibitor screen
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
RZ score, qAC50 and toxicity of 41 potent TREX1 inhibitors from the small-molecule inhibitor screen
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
TREX1 inhibitors suppress tumor progression in vivo
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
TREX1 inhibitors suppress tumor progression in vivo
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Validation of Trex1-KO and double KO MC38 cells
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Validation of Trex1-KO and double KO MC38 cells
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of inducible Trex1 KO in combination with anti-PD-1 immunotherapy
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of inducible Trex1 KO in combination with anti-PD-1 immunotherapy
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of compound #296
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of compound #296
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Immune cell infiltration in tumors treated with compound #296
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Immune cell infiltration in tumors treated with compound #296
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Gating strategy used in Figure 6
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Gating strategy used in Figure 6
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Gating strategy used in Figure 2 and 4
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Gating strategy used in Figure 2 and 4